MX2024006267A - Anticuerpos anti ngf y usos de los mismos - Google Patents

Anticuerpos anti ngf y usos de los mismos

Info

Publication number
MX2024006267A
MX2024006267A MX2024006267A MX2024006267A MX2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A
Authority
MX
Mexico
Prior art keywords
ngf
canine
methods
provides novel
compositions
Prior art date
Application number
MX2024006267A
Other languages
English (en)
Spanish (es)
Inventor
William Brondyk
Jordan Willis
Leila Sevigny
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of MX2024006267A publication Critical patent/MX2024006267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024006267A 2021-11-23 2022-11-23 Anticuerpos anti ngf y usos de los mismos MX2024006267A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163282590P 2021-11-23 2021-11-23
US202263383173P 2022-11-10 2022-11-10
PCT/US2022/080428 WO2023097275A1 (en) 2021-11-23 2022-11-23 Anti-ngf antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024006267A true MX2024006267A (es) 2024-11-08

Family

ID=86540392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006267A MX2024006267A (es) 2021-11-23 2022-11-23 Anticuerpos anti ngf y usos de los mismos

Country Status (8)

Country Link
US (3) US20250011410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436602A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543139A (cg-RX-API-DMAC7.html)
KR (1) KR20240141160A (cg-RX-API-DMAC7.html)
AU (1) AU2022397400A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238769A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006267A (cg-RX-API-DMAC7.html)
WO (1) WO2023097275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2025245092A1 (en) * 2024-05-20 2025-11-27 Invetx, Inc. Anti-ngf antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US8082436B2 (en) 2008-07-08 2011-12-20 Dell Products L.P. Enhanced UEFI framework layer
SG187592A1 (en) * 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
BR112020017701A2 (pt) * 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
TW202237648A (zh) * 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Also Published As

Publication number Publication date
WO2023097275A1 (en) 2023-06-01
AU2022397400A1 (en) 2024-06-06
US20250011410A1 (en) 2025-01-09
EP4436602A4 (en) 2026-07-08
US20240010717A1 (en) 2024-01-11
US20240199727A1 (en) 2024-06-20
CA3238769A1 (en) 2023-06-01
US12378308B2 (en) 2025-08-05
JP2024543139A (ja) 2024-11-19
KR20240141160A (ko) 2024-09-25
US12110322B2 (en) 2024-10-08
EP4436602A1 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
SI2206728T1 (en) Methods for the treatment of bone cancer pain by administration of an antagonist nerve growth factor
ATE548388T1 (de) An den interleukin-4-rezeptor bindende antikörper
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
EA200600254A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
UA102775C2 (uk) Спосіб лікування болю із застосуванням анти-ngf антитіла
WO2004004633A3 (en) Use of tnfalpha antibodies and another drug
MX364874B (es) Anticuerpos de il-6 y uso de los mismos.
AR082390A1 (es) Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
Li et al. Inhibition of chemokine CX3CL1 in spinal cord mediates the electroacupuncture-induced suppression of inflammatory pain
MX2022013894A (es) Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
MX2022011856A (es) Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos.
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
MX2025011192A (es) Fragmentos de fc que se unen a fcrn y metodos de uso
Salazar‐Degracia et al. Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice
Luo et al. Glucocorticoid receptor contributes to electroacupuncture-induced analgesia by inhibiting Nav1. 7 expression in rats with inflammatory pain induced by complete freund's adjuvant
BRPI0416467A (pt) ácido nucléico purificado, célula hospedeira, proteìna purificada, anticorpo, fragmento fab, e, métodos para induzir a produção de tnf alfa, para tratar um paciente, e para triagem para inibidores da il-32
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
ZA202205813B (en) Trpv1 epitopes and antibodies
RU2015147913A (ru) Антитело против рецептора эпидермального фактора роста